HELICOVAXOR
Development of an oral Helicobacter Pylori vaccine
| Coordinatore | SIGMOID PHARMA LIMITED
Organization address
address: THE INVENT CENTRE, DUBLIN CITY UNIVERSITY contact info |
| Nazionalità Coordinatore | Ireland [IE] |
| Totale costo | 1˙809˙000 € |
| EC contributo | 1˙303˙000 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2012 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-10-01 - 2014-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
SIGMOID PHARMA LIMITED
Organization address
address: THE INVENT CENTRE, DUBLIN CITY UNIVERSITY contact info |
IE (DUBLIN) | coordinator | 1˙169˙500.00 |
| 2 |
TELORMEDIX SA
Organization address
address: Via della Posta 10 contact info |
CH (Bioggio) | participant | 108˙500.00 |
| 3 |
GOTOVAX AB
Organization address
address: KORVETTGATAN 1D contact info |
SE (VASTRA FROLUNDA) | participant | 25˙000.00 |
| 4 |
ALLIED AUTOMATION LIMITED
Organization address
address: JAMESTOWN ROAD contact info |
IE (DUBLIN) | participant | 0.00 |
| 5 |
ALMAC DIAGNOSTICS LIMITED
Organization address
address: SEAGOE INDUSTRIAL ESTATE 20 contact info |
UK (CRAIGAVON) | participant | 0.00 |
| 6 |
CORDEN PHARMA SWITZERLAND LLC
Organization address
address: EICHENWEG 1 contact info |
CH (LIESTAL) | participant | 0.00 |
| 7 |
DIAMOND BIOPHARM LIMITED
Organization address
address: "GEMINI HOUSE, EAST WING 4" contact info |
UK (HARLOW) | participant | 0.00 |
| 8 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | participant | 0.00 |
| 9 |
MEDITOX S.R.O
Organization address
address: POD ZAMKEM 279 contact info |
CZ (KONAROVICE) | participant | 0.00 |
| 10 |
PARTICULAR SCIENCES LTD-PSCI
Organization address
address: PARK AVENUE 26 CASTLEKNOCK contact info |
IE (DUBLIN) | participant | 0.00 |
| 11 |
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Organization address
address: College Green - contact info |
IE (DUBLIN) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer. Because eradication requires treatment with multidrug regimens, there exists a very strong need for a vaccine to prevent initial infection.
Immunization with H pylori protein subunits in humans has shown adjuvant-related adverse effects and only moderate effectiveness. However, with much greater knowledge of the molecular basis of infection and having learnt lessons from previous vaccine developments, the current consortium have drawn together three strand that are considered critical to the development of an effective vaccine: - Powerful, safe and multivalent antigens - Powerful, safe and multi-acting adjuvants - Powerful, modular and flexible oral vaccine delivery system
All three of the above innovative technologies have been proven to be effective in doing what they are required to do, namely:
- Antigens – produce antibodies against a number of key H pylori bacterial components - Adjuvants – stimulate the immune cells to produce significant numbers of long lasting antibodies - Delivery – formulate antigens and adjuvants together and target the stomach and intestine
This consortium (HELICOVAXOR) uniquely converges all three into a true vaccine with real potential to protect from H pylori infection. The vaccine is being designed for oral administration, efficacy, safety and temperature stability.
This consortium has assembled leading academic, industrial and regulatory groups, the activities of which will be coordinated to perform analysis of the formulations, efficacy and safety testing of the vaccines and the preparation of a regulatory dossier, all required before the product can enter human clinical studies.
If successful in pre-clinical studies, the consortium will work with vaccine companies to progress human studies and launch the product as a vaccine to confer protection from H pylori infection.'
Introduzione (Teaser)
A European consortium is developing a novel, orally delivered vaccine against Helicobacter pylori. Using encapsulating technology the vaccine will be administered orally, thereby directly reaching the site of H. pylori infection.